US10340030B2ActiveUtilityA1

Systems and methods for identifying cancer treatments from normalized biomarker scores

96
Assignee: BOSTONGENE CORPPriority: Jun 13, 2017Filed: Jun 12, 2018Granted: Jul 2, 2019
Est. expiryJun 13, 2037(~10.9 yrs left)· nominal 20-yr term from priority
G16B 45/00G16H 50/70C12Q 2600/156G06F 16/285G16H 50/30C12Q 2600/158G16H 20/40G16H 20/00G16H 50/50G16H 70/20C12Q 1/6886G16H 20/10G16H 10/20G06F 17/18G16B 5/00G16H 50/20G16B 50/00G16B 40/30G16B 30/00G16B 40/00G16B 20/00G16B 40/20G16B 50/30G16B 25/10G16B 5/20
96
PatentIndex Score
13
Cited by
131
References
22
Claims

Abstract

Techniques for generating therapy biomarker scores and visualizing same. The techniques include determining, using a patient's sequence data and distributions of biomarker values across one or more reference populations, a first set of normalized scores for a first set of biomarkers associated with a first therapy, and a second set of normalized scores for a second set of biomarkers associated with a second therapy, generating a graphical user interface (GUI) including a first portion associated with the first therapy and having at least one visual characteristic determined based on a normalized score of the respective biomarker in the first set of normalized scores; and a second portion associated with a second therapy and having at least one visual characteristic determined based on a normalized score of the respective biomarker in the second set of normalized scores; and displaying the generated GUI.

Claims

exact text as granted — not AI-modified
The invention claimed is: 
     
       1. A system, comprising:
 at least one computer hardware processor; 
 at least one database that stores biomarker information; and 
 at least one non-transitory computer-readable storage medium storing processor-executable instructions that, when executed by the at least one computer hardware processor, cause the at least one computer hardware processor to perform:
 obtaining sequencing data about at least one biological sample of a subject known to have or suspected of having cancerous cells or pre-cancerous cells; 
 accessing, in the at least one database, biomarker information indicating a distribution of values for each biomarker in at least a reference subset of a plurality of biomarkers across a respective group of people, each of the plurality of biomarkers being associated with at least one therapy in a plurality of therapies, the plurality of biomarkers including a first biomarker and the biomarker information including a distribution of values for the first biomarker; 
 determining, using both the sequencing data and the biomarker information:
 a first set of normalized scores for a first set of biomarkers associated with a first therapy in the plurality of therapies, 
 a second set of normalized scores for a second set of biomarkers associated with a second therapy in the plurality of therapies, and 
 a third set of normalized scores for a third set of biomarkers associated with a third therapy in the plurality of therapies, wherein the first set of biomarkers is different from the second set of biomarkers, and wherein determining the first set of normalized scores comprises determining a first normalized score for the first biomarker using the distribution of values for the first biomarker at least in part by: 
 determining an un-normalized score for the first biomarker using the sequencing data, 
 determining a Z-score based on the first distribution of values for the first biomarker, and 
 determining a normalized score for the first biomarker based on the un-normalized score and the Z-score; 
 
 determining, using the first, second, and third sets of normalized scores and a statistical model, respective first, second, and third therapy scores for the first, second, and third therapies; 
 generating a graphical user interface (GUI), wherein the GUI comprises:
 a first portion associated with the first therapy in the plurality of therapies, the first portion including a first plurality of GUI elements, each of the first plurality of GUI elements being associated with a respective biomarker in the first set of biomarkers and having at least one visual characteristic determined based on a normalized score of the respective biomarker in the first set of normalized scores; 
 a second portion associated with the second therapy in the plurality of therapies, the second portion including a second plurality of GUI elements different from the first plurality of GUI elements, each of the second plurality of GUI elements being associated with a respective biomarker in the second set of biomarkers and having at least one visual characteristic determined based on a normalized score of the respective biomarker in the second set of normalized scores; and 
 a third portion associated with the third therapy in the plurality of therapies, the third portion including a third plurality of GUI elements, each of the third plurality of GUI elements being associated with a respective biomarker in the third set of biomarkers and having at least one visual characteristic determined based on a normalized score of the respective biomarker in the third set of normalized scores; and 
 
 displaying the generated GUI. 
 
 
     
     
       2. The system of  claim 1 , wherein determining the first, therapy score comprises:
 determining weights for two or more scores in the first set of normalized scores; and 
 determining the first therapy score as a weighted sum of the two or more scores with summands of the sum being weighted by the determined weights. 
 
     
     
       3. The system of  claim 1 , wherein the processor-executable instructions further cause the at least one processor to perform:
 recommending at least one of the plurality of therapies for the subject based on the determined therapy scores. 
 
     
     
       4. The system of  claim 1 , wherein the plurality of therapies comprise at least two therapies selected from the group consisting of: an anti-PD1 therapy, an anti-CTLA4 therapy, an IL-2 therapy, an IFN alpha therapy, an anti-cancer vaccine therapy, an anti-angiogenic therapy, and an anti-CD20 therapy. 
     
     
       5. The system of  claim 1 , wherein the at least one visual characteristic comprises color of a GUI element and/or size of the GUI element. 
     
     
       6. The system of  claim 1 , wherein the processor-executable instructions further cause the at least one processor to perform:
 in response to receiving, via the GUI, a user selection of the first therapy, presenting, via the GUI, information about at least one biomarker with which at least one of the first plurality of GUI elements is associated. 
 
     
     
       7. The system of  claim 1 , wherein the first portion and the second portion are positioned, relative to one another in the GUI, based on relative magnitude of the first therapy score and the second therapy score. 
     
     
       8. The system of  1 , wherein each of the plurality of biomarkers is selected from the group consisting of: a genetic biomarker, a cellular biomarker, a saccharide biomarker, a lipid biomarker, a heterocyclic biomarker, an elementary compound biomarker, an imaging biomarker, an anthropological biomarker, a personal habit biomarker, a disease-state biomarker, and an expression biomarker. 
     
     
       9. The system of  claim 1 , wherein the sequencing data is one or more of: DNA sequencing data, RNA sequencing data, or proteome sequencing data. 
     
     
       10. The system of  claim 1 , wherein each of the therapies are selected from immunotherapy and targeted therapy. 
     
     
       11. The system of  claim 1 , wherein each of the plurality of biomarkers is selected from the group consisting of biomarkers listed in Table 2. 
     
     
       12. The system of  claim 1 , wherein the statistical model comprises a linear model. 
     
     
       13. The system of  claim 1 , wherein the statistical model comprises a generalized linear model. 
     
     
       14. The system of  claim 1 , wherein the statistical model comprises a neural network model, a Bayesian regression model, an adaptive non-linear regression model, a mixture model, and/or a random forest regression model. 
     
     
       15. At least one non-transitory computer-readable storage medium storing processor-executable instructions that, when executed by at least one computer hardware processor, cause the at least one computer hardware processor to perform:
 obtaining sequencing data about at least one biological sample of a subject known to have or suspected of having cancerous cells or pre-cancerous cells; 
 accessing, in at least one database, biomarker information indicating a distribution of values for each biomarker in at least a reference subset of a plurality of biomarkers across a respective group of people, each of the plurality of biomarkers being associated with at least one therapy in a plurality of therapies, the plurality of biomarkers including a first biomarker and the biomarker information including a distribution of values for the first biomarker; 
 determining, using both the sequencing data and the biomarker information: a first set of normalized scores for a first set of biomarkers associated with a first therapy in the plurality of therapies, a second set of normalized scores for a second set of biomarkers associated with a second therapy in the plurality of therapies, and a third set of normalized scores for a third set of biomarkers associated with a third therapy in the plurality of therapies, wherein the first set of biomarkers is different from the second set of biomarkers, and wherein determining the first set of normalized scores comprises determining a first normalized score for the first biomarker using the distribution of values for the first biomarker at least in part by:
 determining an un-normalized score for the first biomarker using the sequencing data, 
 determining a Z-score based on the first distribution of values for the first biomarker, and 
 determining a normalized score for the first biomarker based on the un-normalized score and the Z-score; 
 
 determining, using the first, second, and third sets of normalized scores and a statistical model, respective first, second, and third therapy scores for the first, second, and third therapies 
 generating a graphical user interface (GUI), wherein the GUI comprises:
 a first portion associated with the first therapy in the plurality of therapies, the first portion including a first plurality of GUI elements, each of the first plurality of GUI elements being associated with a respective biomarker in the first set of biomarkers and having at least one visual characteristic determined based on a normalized score of the respective biomarker in the first set of normalized scores; 
 a second portion associated with the second therapy in the plurality of therapies, the second portion including a second plurality of GUI elements different from the first plurality of GUI elements, each of the second plurality of GUI elements being associated with a respective biomarker in the second set of biomarkers and having at least one visual characteristic determined based on a normalized score of the respective biomarker in the second set of normalized scores; and 
 a third portion associated with the third therapy in the plurality of therapies, the third portion including a third plurality of GUI elements, each of the third plurality of GUI elements being associated with a respective biomarker in the third set of biomarkers and having at least one visual characteristic determined based on a normalized score of the respective biomarker in the third set of normalized scores; and 
 
 displaying the generated GUI. 
 
     
     
       16. The at least one non-transitory computer readable storage medium of  claim 15 , wherein each of the plurality of biomarkers is selected from the group consisting of biomarkers listed in Table 2. 
     
     
       17. The at least one non-transitory computer readable storage medium of  claim 15 , wherein the processor-executable instructions further cause the at least one processor to perform:
 in response to receiving, via the GUI, a user selection of the first therapy, presenting, via the GUI, information about at least one biomarker with which at least one of the first plurality of GUI elements is associated. 
 
     
     
       18. The at least one non-transitory computer readable storage medium of  claim 15 , wherein the first portion and the second portion are positioned, relative to one another in the GUI, based on relative magnitude of the first therapy score and the second therapy score. 
     
     
       19. A method, comprising:
 using at least one computer hardware processor to perform:
 obtaining sequencing data about at least one biological sample of a subject known to have or suspected of having cancerous cells or pre-cancerous cells; 
 accessing, in at least one database, biomarker information indicating a distribution of values for each biomarker in at least a reference subset of a plurality of biomarkers across a respective group of people, each of the plurality of biomarkers being associated with at least one therapy in a plurality of therapies, the plurality of biomarkers including a first biomarker and the biomarker information including a distribution of values for the first biomarker; 
 determining, using both the sequencing data and the biomarker information: a first set of normalized scores for a first set of biomarkers associated with a first therapy in the plurality of therapies, a second set of normalized scores for a second set of biomarkers associated with a second therapy in the plurality of therapies, and a third set of normalized scores for a third set of biomarkers associated with a third therapy in the plurality of therapies, wherein the first set of biomarkers is different from the second set of biomarkers, and wherein determining the first set of normalized scores comprises determining a first normalized score for the first biomarker using the distribution of values for the first biomarker at least in part by:
 determining an un-normalized score for the first biomarker using the sequencing data, 
 determining a Z-score based on the first distribution of values for the first biomarker, and 
 determining a normalized score for the first biomarker based on the un-normalized score and the Z-score; 
 
 determining, using the first, second, and third sets of normalized scores and a statistical model, respective first, second, and third therapy scores for the first, second, and third therapies 
 generating a graphical user interface (GUI), wherein the GUI comprises:
 a first portion associated with the first therapy in the plurality of therapies, the first portion including a first plurality of GUI elements, each of the first of GUI elements being associated with a respective biomarker in the first set plurality of biomarkers and having at least one visual characteristic determined based on a normalized score of the respective biomarker in the first set of normalized scores; 
 
 a second portion associated with the second therapy in the plurality of therapies, the second portion including a second plurality of GUI elements different from the first plurality of GUI elements, each of the second plurality of GUI elements being associated with a respective biomarker in the second set of biomarkers and having at least one visual characteristic determined based on a normalized score of the respective biomarker in the second set of normalized scores; and 
 a third portion associated with the third therapy in the plurality of therapies, the third portion including a third plurality of GUI elements, each of the third plurality of GUI elements being associated with a respective biomarker in the third set of biomarkers and having at least one visual characteristic determined based on a normalized score of the respective biomarker in the third set of normalized scores; and 
 
 displaying the generated GUI. 
 
     
     
       20. The method of  claim 19 , wherein each of the plurality of biomarkers is selected from the group consisting of biomarkers listed in Table 2. 
     
     
       21. The method of  claim 19 , further comprising:
 in response to receiving, via the GUI, a user selection of the first therapy, presenting, via the GUI, information about at least one biomarker with which at least one of the first plurality of GUI elements is associated. 
 
     
     
       22. The method of  claim 19 , wherein the first therapy is associated with a first therapy score and the second therapy is associated with a second therapy score, and wherein the first portion and the second portion are positioned, relative to one another in the GUI, based on relative magnitude of the first therapy score and the second therapy score.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.